Kaijing Liu, Lilija Wehling, Shan Wan, Sofia M E Weiler, Marcell Tóth, David Ibberson, Silke Marhenke, Adnan Ali, Macrina Lam, Te Guo, Federico Pinna, Fabiola Pedrini, Amruta Damle-Vartak, Anne Dropmann, Fabian Rose, Silvia Colucci, Wenxiang Cheng, Michaela Bissinger, Jennifer Schmitt, Patrizia Birner, Tanja Poth, Peter Angel, Steven Dooley, Martina U Muckenthaler, Thomas Longerich, Arndt Vogel, Mathias Heikenwälder, Peter Schirmacher, Kai Breuhahn
INTRODUCTION: The Hippo pathway and its transcriptional effectors yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are targets for cancer therapy. It is important to determine if the activation of one factor compensates for the inhibition of the other. Moreover, it is unknown if YAP/TAZ-directed perturbation affects cell-cell communication of non-malignant liver cells. MATERIALS AND METHODS: To investigate liver-specific phenotypes caused by YAP and TAZ inactivation, we generated mice with hepatocyte (HC) and biliary epithelial cell (BEC)-specific deletions for both factors (YAPKO, TAZKO and double knock-out (DKO))...
March 4, 2024: Cellular and Molecular Life Sciences: CMLS